Patients with histologically confirmed diagnosis of prostate cancer who have not yet developed bone metastases 
Prostate cancer patients with a rise in PSA under hormone therapy. 
PSA criteria: 
Patients who have undergone prostatectomy: any rise in PSA or 
Patients without prostatectomy: 2 consecutive rises in PSA levels relative to a previous reference value, separated by one month. The first measurement must occur one month after the reference value and must be above the reference value. The second confirmatory measurement taken one month after the first measurement must be greater than the first measurement. 
Previous chemotherapy or radiotherapy must have been performed ≥ 8 weeks prior to study entry. 
Eastern Cooperative Oncology Group (ECOG) score of 0, 1 or 2 (patients that spend less than 50% of time in bed during the day) 
Adequate liver function - serum total bilirubin concentration less than 1.5 x upper limit of normal value 
Age: ≥ 18 years 
Patient has given written informed consent prior to any study-specific procedures. Patients with psychiatric or addictive disorders which prevent them from giving their informed consent must not enter the study. 

NCT00391690_inc_T1
Measurement
histologically
NCT00391690_inc_T2
Value
confirmed
NCT00391690_inc_T3
Condition
prostate cancer
NCT00391690_inc_T4
Condition
bone metastases
NCT00391690_inc_T5
Condition
Prostate cancer
NCT00391690_inc_T6
Measurement
PSA
NCT00391690_inc_T7
Value
rise
NCT00391690_inc_T8
Procedure
hormone therapy
NCT00391690_inc_T9
Procedure
prostatectomy
NCT00391690_inc_T10
Measurement
PSA
NCT00391690_inc_T11
Value
rise
NCT00391690_inc_T12
Procedure
prostatectomy
NCT00391690_inc_T13
Negation
without
NCT00391690_inc_T14
Measurement
PSA levels
NCT00391690_inc_T15
Value
rises
NCT00391690_inc_T16
Value
2
NCT00391690_inc_T17
Temporal
consecutive
NCT00391690_inc_T18
Temporal
separated by one month
NCT00391690_inc_T19
Temporal
one month after the reference value
NCT00391690_inc_T20
Value
above the reference value
NCT00391690_inc_T21
Value
first
NCT00391690_inc_T22
Procedure
measurement
NCT00391690_inc_T23
Value
second
NCT00391690_inc_T24
Procedure
measurement
NCT00391690_inc_T25
Temporal
one month after the first measurement
NCT00391690_inc_T26
Value
greater than the first measurement
NCT00391690_inc_T27
Procedure
chemotherapy
NCT00391690_inc_T28
Procedure
radiotherapy
NCT00391690_inc_T29
Temporal
Previous
NCT00391690_inc_T30
Temporal
≥ 8 weeks prior to study entry
NCT00391690_inc_T31
Scope
chemotherapy or radiotherapy
NCT00391690_inc_T32
Measurement
Eastern Cooperative Oncology Group (ECOG) score
NCT00391690_inc_T33
Value
0, 1 or 2
NCT00391690_inc_T34
Measurement
spend time in bed during the day
NCT00391690_inc_T35
Value
less than 50%
NCT00391690_inc_T36
Scope
Eastern Cooperative Oncology Group (ECOG) score of 0, 1 or 2
NCT00391690_inc_T37
Scope
spend less than 50% of time in bed during the day
NCT00391690_inc_T38
Measurement
liver function
NCT00391690_inc_T39
Value
Adequate
NCT00391690_inc_T40
Measurement
serum total bilirubin concentration
NCT00391690_inc_T41
Value
less than 1.5 x upper limit of normal value
NCT00391690_inc_T42
Person
Age
NCT00391690_inc_T43
Value
≥ 18 years
NCT00391690_inc_T44
Condition
psychiatric disorders
NCT00391690_inc_T45
Condition
addictive disorders
NCT00391690_inc_T46
Observation
giving informed consent
NCT00391690_inc_T47
Negation
prevent
NCT00391690_inc_T48
Scope
psychiatric or addictive disorders